Research article · 15 Jun 2021
Conference abstractPublished 10 Oct 2020
Medication Safety Update During COVID-19
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The COVID-19 pandemic and the response of the healthcare system initiates some challenges associated with some of medication shortages and needs of changes on the medication management workflow, additional evidence base associated with the pharmaceutical treatment of COVID-19 complications, and limited availability of personal protective equipment (PPE).the use of automated dispensing cabinets (ADCs). Including Accessing the ADC by using hygiene before and after touching any machine . In some organizations; they disable the fingerprint for users who might be wearing gloves and activate retinal scanning or entry of a username and password until biometric fingerprint identification can resume. If clean gloves are used when accessing the cabinet, they should be discarded before leaving the location, and use hand’s hygiene and store a container of the appropriate cleaning disinfectant nearby to allow those accessing the ADC to disinfect common touched points minimize the risk of contamination, the medications that already removed from the ADC shall not be returned to the specific bin or pocket from which they came. A common secure, oneway return bin should be used for returning unadministered medications to the pharmacy (including controlled substances).Maintaining safe practices in a case of requiring a documented witness, independent double check by another practitioner is a must when removing certain facility-defined high-alert medications from an unprofiled ADC or via override (bypassing the pharmacist’s review of a medication order to obtain a medication from the ADC when assessment of the patient indicates that a delay in therapy would harm the patient) and use ADC dispensing alerts to provide practitioners with critical information about new or unfamiliar medications given that many practitioners may be working outside their normal clinical practice area.hydroxychloroquine or chloroquine : the FDA is aware of reports of serious heart rhythm problems in patients with COVID-19 treated with hydroxychloroquine or chloroquine, often in combination with azithromycin and other QT prolonging medicines. We are also aware of increased usage of these medicines through outpatient prescriptions
Subjects
EngineeringMaterials ScienceAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 9 Feb 2022
Colloidal nanoparticles and unique interfaces-based SARS-CoV-2 detection methods and COVID-19 diagnosis
Other · 23 Nov 2021
The use of UV Light Disinfection Robot to Fight against Covid-19 and other viruses and to use it for different other works
Perspective · 15 Nov 2021
The in vivo nanoparticle vaccination extends covid-19 immunity
Conference abstract · 29 Oct 2021
Significant Contribution to Covid-19 Scientific Community and Nanomaterials Researchers
More from this journal
The newest in Journal of Materials Engineering and Applications.
Conference abstract · 4 Mar 2022
Environmental protection by recovery of lead from waste lead-acid batteries in the form of nanosized lead-oxide powders
Conference abstract · 4 Mar 2022
New nanotechnologies for Energy saving and Resiliency of the Built Environment
Conference abstract · 4 Mar 2022
Method for manufacture photocurable hydroxyapatite slurry that can be applied into stereolithography and physical evaluation according to scaffolds structure
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Materials Engineering and Applications
- SubjectEngineering
- SubjectMaterials Science
- BylineArticles whose byline prints “Fatima Yousef Ghethan”

